A detailed history of Man Group PLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Man Group PLC holds 77,229 shares of APLS stock, worth $2.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
77,229
Holding current value
$2.18 Million
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $2.94 Million - $4.61 Million
77,229 New
77,229 $2.96 Million
Q1 2023

May 15, 2023

SELL
$46.59 - $66.96 $4.73 Million - $6.81 Million
-101,628 Reduced 96.07%
4,156 $274,000
Q4 2022

Feb 14, 2023

SELL
$43.24 - $61.04 $1.63 Million - $2.3 Million
-37,601 Reduced 26.22%
105,784 $5.47 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $5.36 Million - $8.35 Million
119,860 Added 509.5%
143,385 $9.79 Million
Q2 2022

Aug 15, 2022

SELL
$35.07 - $59.21 $1.41 Million - $2.39 Million
-40,327 Reduced 63.16%
23,525 $1.06 Million
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $2.26 Million - $3.46 Million
63,852 New
63,852 $3.24 Million
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $716,242 - $1.15 Million
-23,300 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$31.4 - $69.84 $2.08 Million - $4.62 Million
-66,125 Reduced 73.94%
23,300 $768,000
Q2 2021

Aug 16, 2021

SELL
$40.9 - $64.9 $3.91 Million - $6.21 Million
-95,649 Reduced 51.68%
89,425 $5.65 Million
Q1 2021

May 17, 2021

SELL
$40.8 - $57.39 $1.47 Million - $2.07 Million
-36,126 Reduced 16.33%
185,074 $7.94 Million
Q4 2020

Feb 16, 2021

SELL
$30.79 - $57.2 $821,661 - $1.53 Million
-26,686 Reduced 10.77%
221,200 $12.7 Million
Q3 2020

Nov 16, 2020

SELL
$25.89 - $33.65 $244,919 - $318,329
-9,460 Reduced 3.68%
247,886 $7.48 Million
Q2 2020

Aug 14, 2020

BUY
$24.8 - $38.49 $6.06 Million - $9.41 Million
244,384 Added 1885.39%
257,346 $8.41 Million
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $232,149 - $574,605
12,962 New
12,962 $347,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.1B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.